$CCEP

Transactions in Own Shares

Coca-Cola Europacific Partners (CCEP) repurchased 200,000 shares from 28 Sep to 2 Oct 2026, split between US and London venues, at varying prices. The buyback is part of a EUR 1 billion program announced in Feb 2026. The shares will be cancelled.

Original reporting
Published Oct 5, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 2:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Transactions in Own Shares — source image
Decision brief

The 30-second read

$CCEPNeutralLow
01

Why it matters

The announcement provides a small, positive catalyst for the stock, but the limited scale suggests only short‑term price support.

02

Market read

Primary corporate action with modest relevance; may cause slight upward movement in CCEP shares.

03

What to watch

Potential impact of upcoming earnings or macro‑economic conditions could outweigh the modest buyback effect.

Relevance 5/10Novelty 5/10Timing: same-day announcement

Background

Coca‑Cola Europacific Partners (CCEP) disclosed a recent tranche of its ongoing €1bn share repurchase programme, detailing volumes and prices on both US and London venues.

Company-level read

Ticker impact

$CCEPNeutralMedium confidence
Context

The company announced a new tranche of its share buyback programme, repurchasing 150,000 US-listed shares and 50,000 London-listed shares between 28 Sep and 2 Oct 2026.

Expected impact

slight upward pressure as the market prices in the buyback

Evidence & confidence

The repurchase size is relatively small compared with the overall programme (up to €1bn), so impact is limited but may buoy sentiment briefly.

Market effects

Minimal effect on the consumer goods sector; buybacks are routine for large beverage companies.

Limited to European and US markets where CCEP trades.

Low; the news is company‑specific and does not influence broader market trends.

Counterpoint

The buyback may be a defensive move signaling limited growth opportunities, suggesting caution.

Key entities

  • Coca‑Cola Europacific Partners

    Issuer of the share buyback programme.

  • Goldman Sachs & Co. LLC

    Seller of the repurchased shares.

Related articles

$CCEPMed

UBS reiterates Neutral rating on Coca-Cola Europacific Partners stock

UBS reiterated a Neutral rating on Coca-Cola Europacific Partners (CCEP) with a $107.00 price target, citing 5.4% Q3 organic sales growth forecast. The stock trades at $100.50, above InvestingPro’s Fair Value estimate. UBS expects growth in Europe and Asia Pacific, with potential for raised full-year revenue guidance. CCEP reported H1 2026 revenue of EUR 10.7 billion, up 6.1%, and EPS growth of 10.6%. Analysts have mixed views on its valuation and outlook.

Low

Coca Cola Europacific Partners (ENXTAM:CCEP) Board Exit Leaves Its Undervalued Case In Focus

Coca-Cola Europacific Partners (CCEP) is under scrutiny after independent non-executive director Nathalie Gaveau resigned, prompting a review of board roles. The company's share price is €88.3, down 6.26% over the past month but up 17.42% year-to-date and 116.77% over five years. Analysts suggest CCEP is 8% undervalued with a fair value of €95.68, citing strong long-term growth prospects in emerging markets and digital investments.

$CCEPHigh

Transactions in Own Shares

Coca-Cola Europacific Partners (CCEP) repurchased 403,748 ordinary shares from 7 to 11 September 2026, totaling approximately $43.5 million (USD) and £31.2 million (GBP) on US and London trading venues, respectively. The shares were bought as part of the company's EUR 1 billion share buyback program announced in February 2026. The repurchased shares will be cancelled.

$CCEPHigh

CCEP slips as a fresh Wall Street downgrade adds to valuation concerns

Coca-Cola Europacific Partners (CCEP) fell 3.1% after J.P. Morgan re-initiated coverage with an Underweight rating and a $92 price target, citing valuation concerns and potential slowdown in volume growth. The stock has faced scrutiny due to its premium valuation, despite solid first-half 2026 results. Institutional investors have recently adjusted their positions in CCEP.

$CCEPMedAI 8/10

CCEP (CCEP) Q2 2026 Earnings Call Transcript

Coca-Cola Europacific Partners (CCEP) reported Q2 2026 results on a half-year basis: revenue EUR 10.7B (+6.1%), operating profit EUR 1.5B (+8.1%), operating margin 13.8% (+30 bps), and diluted EPS EUR 2.20 (+10.6%). Free cash flow was EUR 435M in H1; management reaffirmed full-year FCF target of at least EUR 1.7B and completed EUR 600M of a EUR 1B buyback. Risks include Middle East commodity volatility.